Journey Medical (NASDAQ:DERM) Research Coverage Started at Roth Mkm

Roth Mkm began coverage on shares of Journey Medical (NASDAQ:DERM) in a note issued to investors on Friday, StockNewsAPI reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Roth Mkm’s target price would suggest a potential upside of 114.01% from the stock’s previous close.

Journey Medical Stock Performance

DERM opened at $5.14 on Friday. The company has a current ratio of 1.21, a quick ratio of 0.94 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $102.85 million, a price-to-earnings ratio of -16.58 and a beta of 0.79. Journey Medical has a 12 month low of $1.52 and a 12 month high of $8.11. The stock has a 50-day moving average of $4.16.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.27). Journey Medical had a negative return on equity of 32.83% and a negative net margin of 5.20%. The firm had revenue of $13.03 million during the quarter, compared to the consensus estimate of $14.91 million. On average, research analysts forecast that Journey Medical will post -1.02 earnings per share for the current fiscal year.

Institutional Trading of Journey Medical

Several institutional investors and hedge funds have recently modified their holdings of DERM. Nwam LLC purchased a new position in Journey Medical during the first quarter valued at approximately $41,000. Heron Bay Capital Management purchased a new position in Journey Medical during the first quarter valued at approximately $124,000. Finally, Acadian Asset Management LLC increased its holdings in Journey Medical by 687.5% during the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock valued at $817,000 after buying an additional 194,389 shares during the period. Institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.